Can a drug combo wipe out hidden lung cancer cells after surgery?
NCT ID NCT04367311
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II study is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy after lung cancer surgery can clear tumor DNA from the blood. The trial enrolls 100 patients with early-stage non-small cell lung cancer who had detectable tumor DNA after surgery. The goal is to see if this combination reduces the chance of cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (an immunotherapy drug) combined with cisplatin-based chemotherapy
What this could lead to
If successful, this approach could help prevent lung cancer from returning after surgery by using the immune system to target remaining cancer cells.
What could go wrong
This is a mid-stage trial with only 100 participants, so results may not apply to everyone. Immunotherapy can cause immune-related side effects, and the added benefit over standard chemo alone is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
New York University Clinical Cancer Center
New York, New York, 10016, United States
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
Summit Health
Berkeley Heights, New Jersey, 07922, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States